Ver­tex's new dilem­ma: With more pos­i­tive PhI­II da­ta on hand, which of their promis­ing com­bos should go to the FDA, EMA?

Ver­tex $VRTX has a pleas­ant dilem­ma on its hands.

The big biotech re­port­ed that its Phase III tri­al for a cock­tail used to treat cys­tic fi­bro­sis has come in with pos­i­tive re­sults for VX-445, teza­caftor and iva­caftor.

In fact, they’re al­most iden­ti­cal to the Phase III re­sults they got for VX-659 com­bined with teza­caftor and iva­caftor. And that means the ju­ry on which triple will head to reg­u­la­tors on both sides of the At­lantic is still out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.